A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects

Completed · Phase 1

Conditions studied: Erectile Dysfunction

In brief

This study to will compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet.

Key facts

Study ID

NCT00866463

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

18

Starts

2008-10-01

Expected to finish

2008-10-01

Last updated by the study team

2021-02-01

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy males between the ages of 18 and 55 years.
• Body Mass Index of 18 to 30 kg/m2, and a total body weight >50 kg (110 lbs).

You may not qualify if…

• Smoking in excess of the equivalent of 5 cigarettes per day.
• Treatment with an experimental drug within 30 days or sildenafil, vardenafil, tadalfil within 4 days before first study dose.
• Develop blood pressure lowering or experience dizziness, lightheadedness when going from the laying down position to standing position.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.